MOFFITT NGS STAR* Enters Clinical Service

Moffitt’s latest NGS sequencing assay the Moffitt STAR (Solid Tumor Actionable Result) panel was validated by the Moffitt Morsani Molecular Laboratory and launched into service this month at the busy Florida Comprehensive Cancer Center in Tampa.

The assay is based on Illumina’s TruSight Tumor 170 assay which is a next-generation sequencing assay designed to cover 170 genes that are commonly designated as drivers in solid tumors. The assay evaluates both DNA and RNA and focuses on detecting actionable mutations which include SNV, dels, insertions, amplifications, and translocations. Such alterations are the target for many new targetable therapies including anti-EGFR agents, anti BRAF therapies and treatments targeting the Tropomyosin Receptor Kinase fusions (TRK) such as Larotrectinib.

Many key actionable mutations only occur rarely, making detection by single marker tests problematic and wasteful. However, the Moffitt STAR assay now allows the Moffitt molecular laboratory to screen patient tumors for multiple targetable mutations efficiently in a single test using a relatively small amount of nucleic acid extracted from routine formalin fixed, paraffin embedded tissues (FFPE). This important advance enables the Moffitt molecular diagnostic laboratory to effectively evaluate a patient for eligibility to receive treatment with a FDA approved targeted therapy, or be considered for clinical trial enrollment. Moffitt STAR is essentially an “All in one” test that can provide multiple functions.

Moffitt NGS STAR* is an exciting new “all in one” technology advance for Moffitt Cancer Center patients enabling rapid assessment of their tumors for presence of key mutations directing selection of effective approved targeted therapies or for qualification to enroll in the latest generation of clinical trials

Evidence is also emerging the assay, despite its mid size, Moffitt STAR could also reliably measure tumor mutational load and microsatellite instability. These molecular features are often associated with potential response to the latest immune check point inhibitors such as Pembrolizumab which has recently received FDA approval for use in tumors with high microsatellite instability.

Moffitt NGS STAR also provides information on tumor mutational burden and microsatellite instability- key features which may drive patient response to the latest immuno-oncology check point inhibitor therapies

Moffitt NGS STAR can also detect mutations in BRCA genes, a molecular feature that may predict response to parp inhibitors such as olaparib.

Moffitt NGS STAR can be performed on as little as 40ng of input nucleic acid.

Development and launch of Moffitt NGS STAR was made possible through collaboration with industry partners PierianDx and Illumina Inc.

The Moffitt Cancer center is one of the largest in the United States, is consistently ranked in the top cancer centers by U.S. News & World Report. Moffitt Cancer Center has a mission to “contribute to the prevention and cure of cancer” and the vision ” to transform cancer care through service, science, and partnership”

For further details contact anthony.magliocco@moffitt.org

13 thoughts on “MOFFITT NGS STAR* Enters Clinical Service

  1. Very nice post. I simply stumbled upon your blog and wished to mention that I have truly enjoyed surfing around your blog posts. After all I’ll be subscribing in your rss feed and I am hoping you write once more very soon!

  2. I’ve been browsing online more than 10 hours today for скачать виндовс 7 начальная & MOFFITT NGS STAR* Enters Clinical Service , yet I never found any
    interesting article like yours. It is pretty worth enough for me.
    Personally, if all web owners and bloggers made good content as you did, the net will be a lot more useful
    than ever before.

  3. Wow that was strange. I just wrote an very long comment but after
    I clicked submit my comment didn’t appear.

    Grrrr… well I’m not writing all that over again. Anyways,
    just wanted to say superb blog!

  4. I blog quite often and I genuinely thank you for your content.
    This article has truly peaked my interest. I will book mark your website
    and keep checking for new details about once a week. I subscribed to your
    RSS feed too.
    +905323495077

  5. Just desire to say your article is as amazing. The clearness in your post is just cool and i could
    assume you are an expert on this subject. Fine with your permission let me to grab your RSS feed to keep up to date with
    forthcoming post. Thanks a million and please carry on the rewarding
    work.

  6. May I simply just say what a comfort to discover somebody who truly understands what they’re
    discussing on the internet. You certainly know
    how to bring an issue to light and make it important.
    More and more people ought to check this out and understand this side of the story.

    I was surprised that you are not more popular given that you surely have the gift. http://www.mbet88vn.com

  7. I have been surfing online more than 5 hours today for 1/2 Price
    Pro Calgary Painting & MOFFITT NGS STAR* Enters Clinical Service , yet I never found any interesting article like yours.

    It’s pretty worth enough for me. Personally, if all website owners and bloggers made good content as you did, the web will be much more useful than ever before.

Leave a Reply

Your email address will not be published. Required fields are marked *